Eric Yuen, M.D.
Senior Vice President
Chief Medical Officer
Eric Yuen joined Inozyme Pharma in June 2017 and serves as Chief Medical Officer. He has developed biologics and small molecules for the treatment of a variety of diseases, including a number of rare genetic diseases. Dr. Yuen has led departments responsible for Phase I-IV development and submissions of numerous INDs, CTAs, NDAs and MAAs.
His industry experience began at Merck as Director of Clinical Research, where he focused on central nervous system (CNS) and pain indications. He then spent several years at Johnson & Johnson as Vice President of Clinical Development, including four years as the Therapeutic Area Head for CNS; he also served as Head of Clinical Development for four years at a joint venture between Johnson & Johnson and Elan for their portfolio of monoclonal antibodies and vaccines targeting Alzheimer’s disease.
More recently, Dr. Yuen has worked with a number of biotechnology and pharmaceutical companies, helping to develop compounds targeting a variety of rare genetic diseases. Prior to industry, Dr. Yuen was an assistant professor of neurology at the University of Washington, where he conducted clinical research in rare disorders such as ALS and muscular dystrophies.
Dr. Yuen completed his undergraduate education at Stanford University; received his M.D. from the University of Chicago, Pritzker School of Medicine; completed his neurology residency at the University of California at San Francisco (UCSF); and completed his post-doctoral work in the lab at UCSF, where he studied neurotrophic factor signaling.